Skip to content
Triangle logo TriangleGet started
← Full study record

NCT02619682 · OUTCOME

Overall Survival

Alternating Ixazomib Citrate and Lenalidomide as Maintenance Therapy After Stem Cell Transplant in Treating Patients With Multiple Myeloma · Source last updated 2026-01-08

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
COUNT_OF_PARTICIPANTS
Unit
Participants
Interval / dispersion
Not reported
Time frame
Median 4.6 years from start of therapy

What was measured

all MM patients who got post autologous transplant study therapy

Groups in this outcome

Post Autologous Transplant Maintenance

one treatment arm all patients enrolled on study

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Post Autologous Transplant Maintenance30

Reported measurements

Source class 1
Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Post Autologous Transplant Maintenance21Not reportedNot reportedNot reportedNot reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        value
        21
denoms
  1. counts
    1. group Id
      OG000
      value
      30
    units
    Participants
description
all MM patients who got post autologous transplant study therapy
groups
  1. description
    one treatment arm all patients enrolled on study
    id
    OG000
    title
    Post Autologous Transplant Maintenance
param Type
COUNT_OF_PARTICIPANTS
reporting Status
POSTED
time Frame
Median 4.6 years from start of therapy
title
Overall Survival
type
SECONDARY
unit Of Measure
Participants

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice